Biovest to Present at ROTH Capital OC Growth Stock Conference

Biovest to Present at ROTH Capital OC Growth Stock Conference
2011 ROTH OC Conference

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB:"BVTI") today announced that the Company is scheduled to present at the 23rd Annual ROTH Capital Orange County Growth Stock Conference on Monday, March 14th at 4:30 p.m. (PST). The Conference is being held March 13-16 at the Ritz Carlton Hotel, Laguna Niguel, California, and Biovest's presentation can be accessed via a live and archived webcast.

Dr. Carlos F. Santos, Biovest's Senior Vice President, Scientific Affairs, Product Development & Regulatory Affairs, will present an overview of BiovaxID®, a late-stage personalized cancer vaccine developed in collaboration with the National Cancer Institute for the treatment of follicular non-Hodgkin's lymphoma and other B-cell lymphomas. Dr. Santos will also review anticipated upcoming corporate milestones.

Biovest ROTH Conference Presentation Details:

EVENT: ROTH Capital OC Growth Stock Conference
WHEN: Monday, March 14, 2011 at 4:30 p.m. (PST)
WHERE: Ritz Carlton, Laguna Niguel, California
WEBCAST: Available at http://www.biovest.com or at http://www.wsw.com/webcast/roth24/bvti/

To meet with Biovest at this event, please contact Douglas Calder at 813-507-2558 or [email protected]

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin's lymphoma.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQBTM Market with the stock-ticker symbol "BVTI", and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI").

For further information, please visit: http://www.biovest.com

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.